#United States #New York #AEYE Health #Diabetic Retinopathy #Yonatan Raz-Fridman

AEYE Health's Strategic Move for U.S. Market Expansion

AEYE Health, recognized as a leader in AI-powered retinal diagnostics, has made a significant announcement regarding its leadership team. The company has appointed Yonatan Raz-Fridman as its new Chief Business Officer (CBO). His extensive experience in technology entrepreneurship positions him perfectly to accelerate AEYE Health's ambitions as it harnesses the power of artificial intelligence to treat diabetic retinopathy.

Raz-Fridman is not just any executive; he is a visionary entrepreneur with a stellar background in scaling technology companies. Previously, he founded Supersocial, which stands out as a leading studio in the metaverse space, and co-founded Kano Computing, an educational technology startup that revolutionizes how children learn through technology. His proven ability to drive growth and innovation is expected to play a crucial role at AEYE Health.

In his newly appointed role, Raz-Fridman will spearhead the growth strategy across various channels and key accounts. His focus will be to forge strategic partnerships that amplify market reach, ensuring that AEYE Health's groundbreaking technology becomes accessible to millions of patients in the U.S. and beyond.

One of AEYE Health's flagship products is AEYE-DS, which is quickly becoming the fastest-growing diabetic retinopathy screening technology in the United States. This innovative device holds the distinction of being the only FDA-cleared, fully autonomous AI that can screen patients with just one image per eye, requiring no physician interpretation. Remarkably, the process is efficient, only taking one minute, thus addressing the urgent need for diabetic eye examinations. Furthermore, the examination is reimbursable under CPT code 92229, making it an economically viable solution for various healthcare providers.

The Co-Founder and CEO of AEYE Health, Zack Dvey-Aharon, expressed his enthusiasm for this new appointment, stating, “We are thrilled to welcome Yonatan to AEYE Health’s leadership team. His entrepreneurial vision and remarkable track record will be instrumental in accelerating the expansion of AEYE-DS across the United States.” Dvey-Aharon emphasizes the importance of partnerships and strategic channels that Raz-Fridman's experience will bring to the company.

“I’m honored to join AEYE Health at such a pivotal time,” Raz-Fridman remarked concerning his new role. He noted the transformative impact AEYE Health is making in diagnosing diabetic retinopathy through autonomous AI technology. Raz-Fridman is determined to enhance growth initiatives and scale AEYE-DS adoption, ultimately striving to redefine existing care standards for diabetic patients.

AEYE Health stands as a digital health company dedicated to providing fully autonomous, AI-based diagnostic solutions for retinal imaging. The firm aims to deliver the best clinical results with superior usability. By making diagnostic screenings both practical and accurate, AEYE Health enables healthcare providers to conduct routine screenings for diabetic retinopathy, ensuring that diabetic patients receive the necessary care to prevent vision loss.

In conclusion, with Raz-Fridman's leadership at the helm, AEYE Health is expected to widen its market presence in the United States and solidify its status as a trailblazer in retinal diagnostics. The health industry's focus on accessibility and efficiency is now more relevant than ever, and AEYE Health's innovative technology will undoubtedly be at the forefront of that evolution.

For more information about AEYE Health and its groundbreaking products, you can reach out to the AEYE Health Press Team or visit their official website.